Chinese medicine as a therapeutic option for pulmonary fibrosis: clinical efficacies and underlying mechanisms

Y Hao, J Li, L Dan, X Wu, X Xiao, H Yang… - Journal of …, 2023 - Elsevier
Ethnic pharmacological relevance Pulmonary fibrosis (PF) is a fibrotic interstitial lung
disease caused by continuous damage and excessive repair of alveolar epithelial cells, the …

[HTML][HTML] Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases

D Mokra, J Mokry, R Barosova, J Hanusrichterova - Antioxidants, 2023 - mdpi.com
N-acetylcysteine (NAC) is widely used because of its mucolytic effects, taking part in the
therapeutic protocols of cystic fibrosis. NAC is also administered as an antidote in …

[HTML][HTML] Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis

NN Dsouza, V Alampady, K Baby, S Maity… - …, 2023 - Springer
The “Thalidomide tragedy” is a landmark in the history of the pharmaceutical industry.
Despite limited clinical trials, there is a continuous effort to investigate thalidomide as a drug …

SLC15A3 plays a crucial role in pulmonary fibrosis by regulating macrophage oxidative stress

J Luo, P Li, M Dong, Y Zhang, S Lu, M Chen… - Cell Death & …, 2024 - nature.com
Idiopathic pulmonary fibrosis (IPF) is a fatal and irreversible disease with few effective
treatments. Alveolar macrophages (AMs) are involved in the development of IPF from the …

[HTML][HTML] Dihydromyricetin Modulates Nrf2 and NF-κB Crosstalk to Alleviate Methotrexate-Induced Lung Toxicity

AI Matouk, EM Awad, NFG El-Tahawy, AAK El-Sheikh… - Pharmaceuticals, 2023 - mdpi.com
Background: Methotrexate (MTX) is an effective anticancer, anti-inflammatory, and
immunomodulatory agent. However, it induces a serious pneumonitis that leads to …

Potential therapeutic targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis

I Ramli, T Cheriet, AM Posadino, R Giordo, H Zayed… - 2023 - qspace.qu.edu.qa
Pulmonary fibrosis (PF) is a feared component in over 200 interstitial pulmonary diseases,
which are characterized by increased alveolar wall thickness, excessive scarring, and …

Senotherapy for lung diseases

PJ Barnes - Advances in Pharmacology, 2023 - Elsevier
Increasing evidence suggests that there is acceleration of lung ageing in chronic lung
diseases, such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary …

[HTML][HTML] Novel inhalation therapy in pulmonary fibrosis: principles, applications and prospects

M Zheng, W Zhu, F Gao, Y Zhuo, M Zheng… - Journal of …, 2024 - Springer
Pulmonary fibrosis (PF) threatens millions of people worldwide with its irreversible
progression. Although the underlying pathogenesis of PF is not fully understood, there is …

[HTML][HTML] Vinpocetine alleviated alveolar epithelial cells injury in experimental pulmonary fibrosis by targeting PPAR-γ/NLRP3/NF-κB and TGF-β1/Smad2/3 pathways

ZA Hussein, AR Abu-Raghif, NJ Tahseen… - Scientific Reports, 2024 - nature.com
This study aimed to investigate the potential anti-fibrotic activity of vinpocetine in an
experimental model of pulmonary fibrosis by bleomycin and in the MRC-5 cell line …

Chloropicrin Ocular Injury: Biomarkers, Potential Mechanisms, and Treatments

EOM Okoyeocha, N Tewari-Singh - Toxicology Letters, 2024 - Elsevier
Ocular tissue, especially the cornea, is overly sensitive to chemical exposures. The
availability and adoption of chemical threat agent chloropicrin (CP) is growing in the United …